Investing.com - U.S. drugmaker Pfizer (N:PFE) reported better-than-expected quarterly revenue on Tuesday, helped by demand for its pneumonia vaccine and its Hospira (N:HSP) acquisition.
Revenue rose 7% to $14.05 billion in the fourth quarter, ahead of the average analyst estimate of $13.56 billion.
Net income fell to $613 million, or 10 cents per share, from $1.23 billion, or 19 cents per share, a year earlier.
But the company provided full-year revenue and earnings forecasts below analysts' estimates, citing generic competition and a strong dollar.
Pfizer said it expects reported revenue of $49 billion-$51 billion for 2016 and adjusted earnings of $2.20-$2.30 per share.